壳聚糖作为基因递送载体的MUC1基因疫苗治疗胰腺癌的实验研究  

Experimental study on chitosan as a gene delivery carrier combined with MUC1 gene vaccine for the treatment of pancreatic cancer

作　　者：廖恺[1] 毕卓菲[1] 何艳[1] 刘宜敏[1] 

机构地区：[1]中山大学孙逸仙纪念医院放疗科,广东广州510120

出　　处：《岭南现代临床外科》2013年第1期38-40,45,共4页Lingnan Modern Clinics in Surgery

基　　金：广东省科技计划项目(2011B031800241)

摘　　要：目的研究以壳聚糖作为基因递送载体的MUC1基因疫苗诱导小鼠产生特异性体液及细胞免疫应答的作用,为壳聚糖联合MUC1基因疫苗用于胰腺癌的免疫治疗提供初步实验依据。方法将30只小鼠平均分3组,分别接种壳聚糖-MUC1质粒、MUC1质粒及空质粒,通过ELISA法检测小鼠血清MUC1抗体生成情况,通过LDH释放法测定CTL对Capan-2细胞的杀伤活性。结果接种壳聚糖-MUC1质粒后,小鼠血清抗MUC1抗体水平及CTL对Capan-2细胞的杀伤率均明显升高,与其它2组相比有显著性差异(P<0.05)。结论壳聚糖作为一种基因递送载体的MUC1基因疫苗能够有效诱导小鼠产生抗MUC1特异性抗体及产生杀伤MUC1+细胞的CTL,为壳聚糖联合MUC1基因疫苗用于胰腺癌的免疫治疗提供了初步的实验基础。Objective To study the effects of chitosan as a gene delivery carrier combined with MUC1 gene vaccine for inducing specific humoral and cellular immune responses in mice, whereby to provide the preliminary experimental evidence for the immunotherapy in pancreatic cancer. Methods Thirty mice were divided into 3 groups （n=10, each group）, which were injected with chitosan-pDC316-MUC1 plasmid, pDC316-MUC1 plasmid or empty pDC316 plasmid, respectively. ELISA method was used to detect the levels of anti-MUC1 antibody in serum. LDH release assay was used to detect the cytotoxicity of CTL for Capan-2 ceils. Results Compared with the other two groups, the levels of anti-MUC1 antibody and the killing rates of CTL for Capan-2 cells in the chitosan- pDC316-MUC1 plasmid group were significantly higher （P〈0.05）. Conclusion Chitosan combined with MUC1 gene vaccine can induce specific humoral and cellular immune responses in mice effectively, which provides preliminary experimental groundwork for the immunotherapy in pancreatic cancer.

关 键 词：壳聚糖 MUC1 基因疫苗 胰腺癌 

分 类 号：R73-36[医药卫生—肿瘤]